Cancer Research UK appoints new trustee
Cancer Research UK today (5 September 2012) announced the appointment of a new Member and Trustee, Professor Peter Selby, President of the Association of Cancer Physicians and Director of the Leeds Institute of Molecular Medicine.
His appointment takes immediate effect.
Professor Selby is a consultant physician at St James’ University Hospital, the St James Institute of Oncology and Professor of Cancer Medicine at the University of Leeds. He was the first Director of the National Cancer Research Network, which has increased clinical trial activity in the UK and substantially influenced developments in medical research for cancer health care in the UK and across the world.
Michael Pragnell, Chairman of Cancer Research UK, said: “I’m delighted to welcome Professor Peter Selby to our governing Council. He joins Cancer Research UK at an exciting time. His clinical experience and expertise will be enormously valuable in guiding the Charity’s research strategy and will help the Charity to build on its success in fighting cancer through cutting-edge research.”
Now working mainly with patients with urological cancers, Professor Selby’s expertise lies in identifying new targets and biomarkers for cancer therapy. His early clinical research involved anti-viral therapy and included the introduction of the drug Acyclovir into clinical practice as a safe and effective anti-viral drug for cancer patients.
From 2005 – 2010 Professor Selby was Joint Director of the NIHR Clinical Research Network, which was responsible for overseeing the development of clinical trials across the NHS. Professor Selby is also President of the Association of Cancer Physicians and has won the Pfizer Excellence in Oncology Lifetime Achievement Award.
He was awarded a CBE for services to cancer research and cancer care in 2001.
For media enquiries, please contact the Cancer Research UK press office on 020 3469 8300.